HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

cefepime (Maxipime)

structure given in UD

Also Known As:

Maxipime; Axépim; BMY 28142; BMY-28142; Bristol-Myers Squibb brand of cefepime dihydrochloride; Bristol-Myers brand of cefepime dihydrochloride; Elan brand of cefepime dihydrochloride; cefepim; cefepime hydrochloride; Pyrrolidinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, hydroxide, inner salt, (6R-(6alpha,7beta(Z)))-

Networked: 592 relevant articles (105 outcomes, 138 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Nicolau, David P: 15 articles (11/2015 - 06/2004)
2.	Kuti, Joseph L: 9 articles (11/2014 - 07/2005)
3.	Bonomo, Robert A: 5 articles (12/2015 - 10/2005)
4.	Crandon, Jared L: 5 articles (11/2015 - 04/2009)
5.	Roberts, Jason A: 5 articles (10/2015 - 02/2007)
6.	Lipman, Jeffrey: 5 articles (12/2012 - 02/2007)
7.	Jones, Ronald N: 5 articles (04/2009 - 03/2002)
8.	Tam, Vincent H: 4 articles (05/2015 - 09/2002)
9.	Tamura, Kazuo: 4 articles (01/2015 - 08/2006)
10.	McKinnon, Peggy S: 4 articles (08/2009 - 09/2002)

Related Diseases

1.	Infection 06/01/2008 - "Cefepime therapy using a 250 mg/m(2) dose administered every 12 h is adequate to achieve plasma concentrations greater than 8 mug/mL during more than 60% of the dosing interval and is expected to be effective in the treatment of bloodstream infections caused by most gram negative organisms in newborn infants. " 01/01/2000 - "The excellent activity against most Gram negative and Gram positive pathogens suggests that cefepime may be useful in the treatment of serious infections in the described patient population." 01/01/1989 - "The high in vitro activity of cefepime was reflected in its in vivo efficacy against experimental infections in normal and immuno-suppressed mice. " 03/01/2001 - "Treatment with cefepime 50 mg/kg/ dose administered every 8 to 12 h produced a satisfactory clinical response (clinical signs of infection resolved or improved with no evidence of recurrent infection at posttreatment follow-up) in 88 to 100% of patients, comparable with comparator therapy. " 02/01/2008 - "The T>MIC values (8 h) of cefepime suggested that this agent is clinically effective in the treatment of various infections."
2.	Pneumonia (Pneumonitis) 05/01/2008 - "In conclusion, fixed dose combination of Cefepime and Amakacin was more effective in the treatment of nosocomial pneumonia than Cefepime alone." 01/01/1999 - "Our data suggest that cefepime was safe and effective for treatment of severe pneumonia in hospitalized patients." 01/01/2012 - "Patient's pneumonia improved with treatment with cefepime. " 01/01/2013 - "The results of this study show that cefepime is not a reasonable choice for empirical treatment of nosocomial pneumonia and VAP." 01/01/2010 - "We examined these issues in a prospective non-interventional study of 21 consecutive intensive care unit (ICU) adult patients treated with cefepime for nosocomial pneumonia. "
3.	Neoplasms (Cancer) 08/01/1997 - "Cefepime appears to be a candidate for monotherapy in febrile neutropenic cancer patients." 11/01/1993 - "In a pilot study, we evaluated the efficacy and the safety of cefepime, a new cephalosporin with extended-spectrum activity against both Gram-positive and Gram-negative bacteria, as empirical monotherapy for 108 febrile episodes in 84 granulocytopenic cancer patients. " 06/01/2012 - "Cefepime efficacy for treatment of febrile neutropenia (FN) in cancer adult patients is a controversial issue. " 01/01/2002 - "The aim of this study was to prospectively evaluate the effectiveness of cefepime monotherapy in the treatment of cancer patients with febrile granulocytopenia (< 1000 leukocytes/muL and/or < 500 neutrophils/muL). " 12/01/2006 - "Cefepime monotherapy is a safe and feasible option for treatment of childhood cancer patients with febrile neutropenia."
4.	Neutropenia 08/01/1999 - "It is concluded that cefepime monotherapy appeared both safe and effective as empirical therapy in patients with febrile neutropenia." 08/15/2010 - "A sensitivity analysis based solely on the 24 febrile neutropenia trials did not show a statistically significant increase in mortality with cefepime use (ARD per 1000 population, 9.67; 95% CI, -2.87 to 22.21). " 08/01/1999 - "The purpose of this phase II trial was to evaluate the efficacy and safety of cefepime monotherapy in patients with neutropenia expected to last more than 7 days. " 09/01/2015 - "While guidelines recommend empirical cefepime therapy in febrile neutropenia, the mortality benefit of cefepime has been controversial. " 06/01/2012 - "To describe the demographic characteristics and general mortality of patients suffering from febrile neutropenia treated with cefepime in a fourth-level Latin American hospital. "
5.	Bacterial Infections (Bacterial Infection) 10/01/2002 - "The safety and efficacy of cefepime empiric monotherapy compared with standard broad-spectrum combination therapy for hospitalized adult patients with moderate to severe community-acquired bacterial infections were evaluated. " 11/01/1993 - "We evaluated the efficacy of cefepime 1 g bd as treatment for acute, moderately severe bacterial infection in 239 hospitalized patients (mean age 60 years). " 03/01/2001 - "Four clinical trials of cefepime for the treatment of serious bacterial infections enrolled 259 children with LRTI. " 11/01/1993 - "A non-comparative, multicentre study of cefepime in the treatment of serious bacterial infections." 01/01/2014 - "Cefepime may be given intramuscularly at 12 h intervals to combat susceptible bacterial infections. "

Related Drugs and Biologics

1.	Ceftazidime (Fortum)
2.	Amikacin (A.M.K)
3.	meropenem (Merrem)
4.	Ceftriaxone (Ceftriaxon)
5.	Cefotaxime (Kendrick)
6.	cefepime (Maxipime)
7.	Imipenem
8.	Piperacillin
9.	tazobactam
10.	Cephalosporins (Cephalosporin Antibiotics)

Related Therapies and Procedures

1.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
2.	Cholecystectomy
3.	Antibiotic Prophylaxis
4.	Drug Therapy (Chemotherapy)
5.	Renal Replacement Therapy (Therapies, Renal Replacement)